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Background. Human immunodeﬁciency virus (HIV)-1 elite controllers (ECs) represent an ideal population to
study the effects of HIV persistence on chronic inﬂammation in the absence of antiretroviral therapy (ART).
Methods. Twenty inﬂammatory markers measured in cohorts of ECs, HIV suppressed noncontrollers, and
HIV-uninfected controls were compared using rank-based tests and partial least squares discriminant analysis
(PLSDA). Spearman correlations were determined among the inﬂammatory markers, residual viremia by the
single-copy assay, and CD4+ T cell slope.
Results. Signiﬁcant differences were seen between cohorts in 15 of the soluble inﬂammatory markers. Human
immunodeﬁciency virus-1 ECs were found to have the highest levels for all of the markers with the exception of
RANTES. In particular, median levels of 7 inﬂammatory markers (soluble CD14 [sCD14], interferon [IFN]-γ,
IFN-γ-inducible protein [IP]-10, interleukin [IL]-4, IL-10, sCD40L, and granulocyte-macrophage colony-stimulating
factor) were twice as high in the HIV-1 ECs compared with either of the HIV-suppressed or uninfected groups.
Multivariate PLSDA analysis of inﬂammatory markers improved differentiation between the patient cohorts, dis-
cerning gender differences in inﬂammatory proﬁle amongst individuals on suppressive ART. Soluble markers of
inﬂammation in ECs were not associated with either levels of residual HIV-1 viremia or CD4+ T cell decline.
Conclusions. Despite maintaining relatively low levels of viremia, HIV-1 ECs had elevated levels of a set of key
inﬂammatory markers. Additional studies are needed to determine whether ECs may beneﬁt from ART and to
further evaluate the observed gender differences.
Keywords. antiretroviral therapy; gender; HIV elite controllers; inﬂammation; low-level viremia.
The use of antiretroviral therapy (ART) has led to a dra-
matic decline in the mortality rates of individuals
infected with human immunodeﬁciency virus (HIV).
However, the life expectancy of patients with HIV
may be shorter compared with the general population,
even for individuals on ART with relatively preserved
CD4+ cell counts [1, 2]. A signiﬁcant contributor to
the excess mortality is likely from non-acquired im-
mune deﬁciency syndrome (AIDS)-deﬁning events,
which represent a growing cause of morbidity and mor-
tality in patients infected with HIV [3, 4]. In particular,
patients infected with HIV have been found to be at
higher risk for cardiovascular disease and serious card-
iac events [5, 6]. One proposed mechanism involves
elevated levels of inﬂammation found in HIV patients
on ART compared with those who are HIV-uninfected.
Soluble markers of inﬂammation have been associated
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with elevated arterial wall inﬂammation [7] and coronary artery
disease [8, 9] in patients infected with HIV. In addition, soluble
markers of inﬂammation have been found to better predict
non-AIDS-deﬁning events than cellular markers of T-cell acti-
vation [10].
Human immunodeﬁciency virus-1 elite controllers (ECs)
represent an exceptional group of patients who are able to sup-
press HIV-1 viremia in the absence of ART. Human immuno-
deﬁciency virus-1 ECs represent an ideal population to study
the effects of HIV low-level viremia on systemic inﬂammation
in the absence of any ART-speciﬁc effects. Elite controllers have
stronger HIV-speciﬁc CD8+ T-cell responses and higher levels
of T-cell activation compared with either chronically HIV-
infected patients on suppressive ART or HIV-uninfected indi-
viduals [11]. Furthermore, T-cell activation has been linked to
lower CD4+ T-cell counts in this population [12]. However,
relatively little is known about the effects of systemic inﬂam-
mation and soluble markers of innate immune activation in
HIV-1 ECs. There is evidence that ECs have elevated levels of
C-reactive protein [13], innate immune system activation [14],
and plasma lipopolysaccharide (LPS), which is related to the
mucosal translocation of bacterial products and is associated
in noncontrollers with elevated levels of soluble monocyte
and macrophage markers of inﬂammation [8]. In addition,
we have previously reported increased sCD14 in HIV-1 ECs
compared with HIV-suppressed subjects and increased coro-
nary atherosclerosis compared with HIV-uninfected controls
[15]. However, the role that chronic low-level viral replication,
which can be suppressed with combination ART, has on this
phenomenon is unknown. In this follow-up study, we hypoth-
esize that chronic low-level viral replication is associated with
systemic inﬂammation in ECs and in turn with CD4+ T-cell
loss. To test these hypotheses, we have (1) expanded both
the number of ECs and the types of inﬂammatory markers
tested, (2) evaluated the relationship between low-level viral
load and soluble markers of inﬂammation in HIV-1 ECs,
and (3) determined the relationship between soluble markers
of inﬂammation with viral load and CD4+ T cell decline in
HIV-1 ECs.
MATERIALS AND METHODS
Study Subjects
Human immunodeﬁciency virus-1 ECs able to suppress HIV-1
viral load in the absence of ART were identiﬁed from the Inter-
national HIV Controllers Study [16]. Levels of inﬂammation in
42 HIV-1 ECs were compared with 2 comparison cohorts: 80
HIV-suppressed, chronically infected, HIV-1 non-ECs (“HIV
suppressed”) and 43 HIV-uninfected individuals. Both compar-
ison cohorts were previously described and included individuals
ages 40–60 with no known cardiovascular or renal disease who
underwent computed tomography angiography [15].
Measurement of Human Immunodeﬁciency Virus-1 RNA and
Soluble Markers of Inﬂammation
Low-level HIV-1 viral load was measured using the single-copy
assay as previously described [17]. The limit of detection was
standardized to the highest limit for any individual (0.9 cop-
ies/mL). Four soluble markers of inﬂammation previously asso-
ciated with coronary artery disease and HIV disease progression
were measured in the plasma by enzyme-linked immunosor-
bent assays: soluble CD14 (sCD14), monocyte chemoattractant
protein (MCP)-1, high-sensitivity interleukin (IL)-6 (R&D Sys-
tems), and sCD163 (Trillium Diagnostics). In addition, 16 ad-
ditional soluble markers of inﬂammation were evaluated in the
plasma by the Luminex xMAP assay: interferon (IFN)-γ, IFN-γ-
inducible protein (IP)-10, IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10,
IL-12p70, IL-13, tumor necrosis factor-α, macrophage inﬂam-
matory protein (MIP)-1α, MIP-1β, RANTES, sCD40L, and
granulocyte-macrophage colony-stimulating factor (GM-CSF).
Statistical Analysis and Multivariate Analysis
The solublemarkers of inﬂammation were compared between the
HIV-1 ECs and cohorts of HIV-suppressed and HIV-uninfected
controls using k-sample rank-based tests or the Jonckheere-
Terpstra test for trend. Changes in absolute CD4+ T-cell count
over time were calculated using a linear regression model to
determine the slope. Spearman correlations were evaluated be-
tween the soluble markers of inﬂammation in ECs with residual
viremia or CD4+ T-cell slope. Multiple testing was controlled
using a 5% false discovery rate based on the Benjamini-Hochberg
approach. Human immunodeﬁciency virus-1 ECs were included
in the CD4+ T-cell slope analysis if they had at least 3 recorded
CD4+ T-cell measurements in the absence of antiretroviral treat-
ment. A subset of these EC participants were described in a pre-
vious report of CD4+ cell decline and residual viremia [17].
Partial least squares discriminant analysis (PLSDA) [18] was
used to determine multivariate biomarker proﬁles that best dis-
tinguished between EC, HIV-suppressed, and HIV-uninfected
subjects. We also created a separate model to evaluate proﬁle
differences between HIV-suppressed men and women. In
brief, PLSDA uses covariance to identify linear combinations
of independent, or latent, variables that best differentiate be-
tween the HIV cohorts. Every patient sample is assigned a
score, which can be visualized in the latent variable space
(score plots). Latent variable loadings (loadings plots) can
then be used to identify biomarker proﬁles associated with dif-
ferent cohort classes. High-sensitivity IL-6 measurements were
excluded from PLSDA analysis due to missing measurements in
several samples. Variable Importance Projection (VIP) scores
can be calculated for each biomarker in the model and are a
commonly used measure for feature selection. In general, vari-
ables that contribute considerably to classiﬁcation in the model
have a VIP score >1, and variables with a VIP score <1 are good
candidates to remove. To reduce the risk of overﬁtting, we
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included only biomarkers with a VIP score >1 in all models. In-
dividuals where 3 or more biomarker measurements were miss-
ing were excluded; this included 1 HIV-negative individual and
1 HIV-suppressed individual. Before analysis, all data were nor-
malized with mean centering and variance scaling. Both of
these are commonly used methods for preprocessing data be-
fore multivariate analysis. Mean centering involves subtracting
the mean from each column of data. Variance scaling involves
dividing each column of data by the standard deviation of that
column. Both of these methods ensure that the model is not bi-
ased towards variables with naturally higher raw values or var-
iance than other variables. Cross-validation is commonly
performed to evaluate how the models perform on unknown
data. We performed cross-validation by iteratively excluding
random subsets (∼10%) of data during model calibration,
then we used this excluded data to test model predictions.
RESULTS
Human Immunodeﬁciency Virus-1 Elite Controllers Have
Elevated Soluble Markers of Inﬂammation
We compared levels of 20 soluble markers of inﬂammation
amongst 42 HIV-1 ECs, a previously described cohort of 80
HIV-suppressed chronically infected non-ECs, and 43 HIV-
uninfected participants, all of whom were between the ages of
40–60 [15]. There were no signiﬁcant differences in age between
the 3 groups (median 49 years for all 3 groups, P = .78; Table 1).
The HIV-1 ECs had a higher proportion of male participants,
but this was also not statistically signiﬁcant (%male: 81% ECs vs
69% HIV-suppressed vs 67% HIV-uninfected, P = .31). There
were no signiﬁcant difference in the duration of HIV infection
between HIV-1 ECs and suppressed individuals (P = .64), but
HIV-1 ECs did have higher CD4+ cell counts (Table 1).
A comparison of the 20 soluble markers of inﬂammation
showed signiﬁcant differences between cohorts in 15 of the
markers (Table 2). Of the soluble inﬂammatory markers that
differed between groups, the HIV-1 ECs were found to have
the highest levels for all of the markers, with the exception of
RANTES. In particular, median levels of 7 inﬂammatory mark-
ers (sCD14, IP-10, IL-4, IL-10, sCD40L, IFN-γ, and GM-CSF)
were twice as high in the HIV-1 ECs compared with either of
the HIV-suppressed or uninfected groups (Figure 1). For the
soluble markers sCD14 and IL-4, the median values were
more than 3 times as high in HIV-1 ECs compared with either
of the other groups.
Multivariate Soluble Inﬂammatory Markers Model Improve the
Identiﬁcation of Elite Controllers
We sought to discover a multivariate biomarker proﬁle that best
distinguished between ECs, HIV-suppressed, and HIV-
uninfected subjects. For this analysis, PLSDA modeling was
performed using 11 of the soluble markers of inﬂammation
that contributed best to the classiﬁcation of subjects in each
model (VIP score >1). With this combination of markers, the
model was able to categorize ECs with 86% classiﬁcation accu-
racy and 85% cross-validation accuracy (Figure 2A and B). The
use of this multivariate inﬂammatory proﬁle was more accurate
for differentiating ECs than using any of the most signiﬁcant
soluble markers individually (Figure 2C).
The EC classiﬁcation accuracy of the PLSDA model was bet-
ter for men than for women (85% men vs 75% women). Closer
inspection revealed that this was at least partially due to eleva-
tion of inﬂammatory markers in HIV-suppressed women,
which was not observed in men. When levels of inﬂammatory
markers were compared between HIV-suppressed men and
women, sCD163 and sCD14 levels were signiﬁcantly higher in
women after correcting for multiple comparisons: sCD163 and
sCD14 (men vs women, sCD163: 1077 vs 1596 ng/mL, P = .001;
sCD14: 314 vs 1854 ng/mL, P < .001). Although sCD14 levels
were 1.7 times higher in HIV-suppressed versus uninfected
Table 1. Baseline Characteristics of the HIV ECs, HIV-Suppressed, and HIV-Uninfected Patient Cohortsa
Variable ECs (N = 42) Suppressed (N = 80) Uninfected (N = 43) P Value
Age (years) 49 [45–55] 49 [45–53] 49 [44–51] .78
Gender (%male) 81% 69% 67% .31
Race .16
White (%) 74% 56% 53%
Black (%) 19% 36% 40%
Other (%) 2% 6% 7%
Unknown (%) 5% 1% 0%
CD4+ count (cells/µL) 807 [690–1043] 534 [357–762] <.01
Duration of HIV infection (years) 16 [10–20] 15 [10–20] .64
Duration of ART (years) 9 [5–12]
Bolded P value represents statistical significance.
Abbreviations: ART, antiretroviral therapy; ECs, elite controllers; HIV, human immunodeficiency virus.
a Significance testing by Kruskal-Wallis, Wilcoxon rank-sum, or χ2 tests. Reported values are median [Q1–Q3] or percentages.
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men, the levels of sCD14 was 6.2 times higher in HIV-sup-
pressed versus uninfected women (Supplementary Tables 1
and 2). Baseline demographics showed no signiﬁcant differenc-
es between HIV-suppressed and uninfected participants within
each gender (Supplementary Table 3), but the proportion of
black participants was higher in HIV-suppressed women than
men (56% vs 27%; Supplementary Table 4).
To explore differences in multivariate inﬂammatory proﬁles
between HIV-suppressed men and women, we generated a sepa-
rate PLSDAmodel explicitly focused on this. We found that HIV-
suppressed women had distinct multivariate inﬂammatory
proﬁles and clustered separately from HIV-suppressed men,
HIV-negative men, and HIV-negative women (Figure 3A). The
multivariate proﬁle for HIV-suppressed women showed higher
levels of CD163, sCD14, and IL-6 and lower levels of GM-CSF,
IL-10, IL-13, and IL-1β (Figure 3B). This proﬁle was more accu-
rate for classifying these groups that any one of these factors alone.
Relationship Between Soluble Markers of Inﬂammation, Low
Level Viremia, and CD4+ T-cell Kinetics
CD4+ cell counts were collected over a median 6.7 years in the
ECs (Q1–Q3: 3.6–10.0 years). The CD4+ T-cell slope was
signiﬁcantly associated with plasma residual viremia (Spearman
r = −0.37, P = .02). In addition, the viral loads were stratiﬁed
into the following 3 categories: <1 copy/mL, 1–10 copies/mL,
and >10 copies/mL. The median (interquartile range [IQR])
viral loads for the 3 categories were as follows: <1 copy: 0.9
(IQR, 0.9–0.9) copies/mL, 1–10 copies/mL: 4.5 (IQR, 1–5) cop-
ies/mL, and >10 copies/mL: 41.5 (IQR, 17–86) copies/mL. A
signiﬁcant trend was detected in this stratiﬁed analysis of higher
viral loads associated with greater rates of CD4+ T cell decline in
HIV-1 ECs (Figure 4).
The relationship of residual viremia and CD4+ T-cell slopes
were also evaluated with each of the 20 soluble markers of
inﬂammation. The only notable association was between levels
of residual viremia and IP-10 levels (Table 3), although statisti-
cal signiﬁcance did not hold after adjustment for multiple
comparisons.
DISCUSSION
In the present study, we report one of the largest analysis to date
of soluble markers of inﬂammation in HIV-1 ECs and its rela-
tionship with low-level plasma viremia and CD4+ T cell decline.
Table 2. Soluble Markers of Inﬂammation Between Participant Cohortsa
Soluble Markerb ECs Suppressed Uninfected Kruskal–Wallis P Value
sCD163 972 [835–1487] 1264 [823–1898] 862 [652–1295] .03
sCD14 1292 [1079–1649] 428 [222–1589] 213 [123–375] <.001
MCP-1 258 [216–288] 264 [196–366] 229 [190–276] .21
hsIL-6 1.1 [0.7–2.0] 1.0 [0.7–1.6] 0.9 [0.5–1.6] .48
IP-10 461 [239–689] 225 [127–354] 182 [103–330] <.001
IL-1β 5 [3–8] 2 [1–4] 5 [3–9] <.001
IL-4 16 [9–24] 0 [0–0.4] 0 [0–44] <.001
IL-5 2.1 [1.4–3.7] 0.9 [0.5–1.6] 1.5 [0.9–2.4] <.001
IL-6 5 [3–8] 6 [3–10] 7 [3–14] .25
IL-8 23 [13–36] 8 [5–13] 14 [9–26] <.001
IL-10 11 [7–14] 5 [2–7] 5 [3–13] <.001
IL-12p70 15 [9–62] 10 [6–16] 13 [9–21] .003
IL-13 9 [5–18] 4 [1–7] 8 [3–22] <.001
TNF-α 17 [13–27] 12 [8–15] 14 [10–19] <.001
MIP-1α 11 [5–18] 5 [3–8] 7 [5–10] <.001
MIP-1β 43 [26–81] 31 [21–46] 42 [27–79] .01
RANTES 1393 [876–2221] 2579 [2216–3200] 2253 [1625–3557] <.001
sCD40L 2247 [1185–3860] 629 [344–1235] 1063 [452–1386] <.001
IFN-γ 71 [27–205] 18 [11–32] 30 [16–92] <.001
GM-CSF 43 [32–102] 13 [8–18] 18 [12–29] <.001
Abbreviations: ECs, elite controllers; GM-CSF, granulocyte-macrophage colony-stimulating factor; HIV, human immunodeficiency virus; hs, high-sensitivity; IFN,
interferon; IL, interleukin; IP-10, IFN-γ-inducible protein 10; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; sCD163, soluble
CD163; TNF, tumor necrosis factor.
a Multiple testing was controlled using the Benjamini-Hochberg approach. Adjusted P values with a <5% false discovery rate are highlighted in bold.
b The sCD163, sCD14, MCP-1, soluble TNF-receptor I, and hsIL-6 levels were measured using enzyme-linked immunosorbent assays, and the remaining soluble
markers were measured by a Luminex-based methodology. The sCD14 and sCD163 values are in ng/mL and the other markers in pg/mL.
Reported values are median [Q1-Q3].
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Figure 1. Levels of soluble CD14 (sCD14) (A), interferon-γ-inducible protein (IP)-10 (B), interleukin (IL)-4 (C), IL-10 (D), sCD40L (E), interferon (IFN)-γ (F),
and granulocyte-macrophage colony-stimulating factor (GM-CSF) (G) among human immunodeﬁciency virus (HIV)-1 elite controllers, HIV-suppressed, and
HIV-uninfected controls. Abbreviation: ECs, elite controllers.
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Figure 2. Partial least squares discriminant analysis (PLSDA) reveals elite controller (EC) plasma proﬁles of inﬂammatory markers are distinct from human
immunodeﬁciency virus (HIV)-negative and HIV-suppressed proﬁles. (A) Partial least squares discriminant analysis identiﬁed a multivariate proﬁle of 11
inﬂammatory markers that was able to classify ECs with 86% classiﬁcation accuracy and 85% cross-validation accuracy (green dots, elite controllers;
blue dots, HIV negative; red dots, HIV suppressed). (B) Latent variable 1 (LV1) represents the multivariate proﬁle that differentiates EC from HIV-uninfected
and HIV-suppressed, indicating that the EC proﬁle was associated with elevation of soluble CD14 (sCD14), interferon-γ-inducible protein (IP)-10, interferon
(IFN)-γ, tumor necrosis factor (TNF)-α, macrophage inﬂammatory protein (MIP)-1β, sCD40L, interleukin (IL)-1β, IL-8, IL-10, granulocyte-macrophage colony-
stimulating factor (GM-CSF), and reduced RANTES. (C) Classiﬁcation error rates of the 3 most highly predictive markers and all markers in combination.
Abbreviation: VIP, variable importance projection.
Figure 3. Human immunodeﬁciency virus (HIV)-suppressed men and HIV-suppressed women have distinct inﬂammatory proﬁles. (A) Partial least squares
discriminant analysis revealed distinct inﬂammatory proﬁles in HIV-suppressed women (red circles) compared with HIV-uninfected women (blue circles).
Human immunodeﬁciency virus-suppressed men (red squares) and HIV-uninfected men (blue squares) clustered more closely in the multivariate space.
Model performed with 89% classiﬁcation accuracy and 88% cross-validation accuracy for classifying HIV-suppressed women. (B) Human immunodeﬁciency
virus-suppressed women were associated with increased soluble CD163 (sCD163), sCD14, and interleukin (IL)-6, and decreased IL-1β, IL-10, IL-13, and
granulocyte-macrophage colony-stimulating factor (GM-CSF).
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Our results show that ECs have increased inﬂammatory markers
and unique inﬂammatory signatures in multivariable models
compared with HIV-suppressed and HIV-uninfected individu-
als. Furthermore, we demonstrate that this heightened inﬂamma-
tion could not easily be explained by HIV-1 plasma viral load and
was not signiﬁcantly associated with CD4+ T cell decline in this
population.
There is increasing evidence that even in the absence of clini-
cally sustained high-level viremia, ECs have higher levels of T-cell
and monocyte/macrophage activation, can exhibit progressive
CD4+ T cell decline [14, 17, 19], and have higher subclinical ath-
erosclerosis than HIV-suppressed patients [13, 15]. The results of
this study demonstrate that these 2 clinically relevant processes,
viral replication and systemic inﬂammation, may be driven by
distinct pathways. Human immunodeﬁciency virus-1 ECs were
found to have signiﬁcantly higher levels of several inﬂammatory
markers, most prominently sCD14 and IL-4, but also IP-10, IL-
10, sCD40L, IFN-γ, and GM-CSF. Soluble CD14 is marker of
monocyte/macrophage activation and bacterial translocation
[20, 21], and levels of sCD14 have been associated with athero-
sclerotic disease in both HIV-infected patients [9] and HIV-
uninfected individuals [22]. Our results are also supported by
previous ﬁndings that show an elevated level of LPS and proin-
ﬂammatory CD14+CD16+ monocytes in ECs [12, 14, 23].Despite
the reported preservation of gut mucosal CD4+ cells in ECs [24],
these results are concerning for increased gut mucosal dysfunc-
tion and bacterial translocation in ECs. The elevated levels of IL-4
in ECs was surprising because IL-4 has been associated with a
Th2-dominant T-cell activity, and HIV controllers have been
found to have similar levels of IL-4-producing CD4+ cells com-
pared with noncontrollers on ART and to maintain an efﬁcient
Th1 cellular response to HIV [25]. Interleukin-4 has been found
to both enhance [26, 27] and inhibit HIV production [28, 29] de-
pending on the cell type. Interleukin-4 has been found to de-
crease CCR5 expression, and promoter polymorphisms that
increase IL-4 transcription has been associated with delayed dis-
ease progression [30]. A number of the other elevated inﬂamma-
tory markers in ECs (eg, IP-10, IL-10, sCD40L, IFN-γ) have
previously been associated with markers of HIV disease progres-
sion in ECs [31] and noncontrollers [32–34], and can be lowered
in the setting of ART [35–37].The heightened inﬂammatory state
found in ECs may suggest a beneﬁt for ART treatment, and, in
fact, a small pilot study demonstrated trends in the lowering of
inﬂammatory markers, including sCD14, in HIV controllers
after initiation of ART [38]. These ﬁndings should be further ex-
plored in larger prospective studies.
Figure 4. CD4+ cell slope by human immunodeﬁciency virus (HIV)-1
plasma viral load category. Median CD4+ cell slope, interquartile range,
and number of elite controllers in each group are listed at the bottom.
Table 3. Correlations Between HIV-1 Viral Load and Soluble
Markers of Inﬂammation in HIV-1 ECsa
Soluble Markerb Spearman r P Value
sCD163 0.10 .55
sCD14 0.02 .88
MCP-1 0.19 .25
hsIL-6 0.01 .93
IP-10 0.37 .02
IL-1β 0.27 .09
IL-4 −0.12 .46
IL-5 −0.11 .51
IL-6 0.02 .88
IL-8 0.05 .75
IL-10 −0.10 .54
IL-12p70 −0.09 .57
IL-13 −0.16 .32
TNF-α 0.26 .10
MIP-1α 0.05 .75
MIP-1β 0.00 .98
RANTES −0.07 .67
sCD40L 0.13 .41
IFN-γ 0.00 .98
GM-CSF −0.02 .89
Abbreviations: ECs, elite controllers; GM-CSF, granulocyte-macrophage
colony-stimulating factor; HIV, human immunodeficiency virus; hs, high-
sensitivity; IFN, interferon; IL, interleukin; IP-10, IFN-γ-inducible protein 10;
MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory
protein; sCD163, soluble CD163; TNF, tumor necrosis factor.
a Multiple testing was controlled using the Benjamini-Hochberg approach.
None of the correlations were found to have a <5% false discovery rate.
b The sCD163, sCD14, MCP-1, soluble TNF-receptor I, and hsIL-6 levels were
measured using ELISA, and the remaining soluble markers were measured by
a Luminex-based methodology.
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The multivariable PLSDA modeling revealed that the use of
multivariate biomarker proﬁling with combinations of inﬂam-
matory markers improved our ability to categorize participants
within the cohorts. The strength of partial least squares model-
ing for the analysis of inﬂammatory biomarkers lies in its ability
to create predictive models in situations when traditional mul-
tiple linear regression is inappropriate, such as in the setting of a
large number of factors and/or factors that are highly collinear.
Given the increasing focus on soluble markers of inﬂammation
and the growing diversity of candidate biomarkers, such an ap-
proach may represent another step in improving their clinical
predictive value. In addition, the PLSDA modeling revealed a
gender difference because the inﬂammatory proﬁle for female
HIV-suppressed participants tended to be different than female
HIV-uninfected participants, whereas male HIV-suppressed
participants had similar biomarker proﬁles compared with
male HIV-uninfected participants. The most prominent inﬂam-
matory marker differences in HIV-suppressed women were the
signiﬁcantly higher levels of sCD14 and sCD163, although this
analysis was confounded by the fact that the proportion of black
participants was much higher for HIV-suppressed women
compared with men. These intriguing ﬁndings (1) potentially
support reports of gender- and race-speciﬁc differences in in-
ﬂammation [39–41] and coronary artery disease in HIV-infected
individuals [42, 43] and (2) highlight the need for additional
studies on this issue.
Although HIV controllers maintain persistent low levels of
HIV viral load, they are at risk of progressive CD4+ cell decline
[44]. Whereas an actively engaged adaptive immune system
contributes to virologic control, it does not completely suppress
viral replication. CD4+ cell decline in ECs was signiﬁcantly as-
sociated with levels of residual viremia [17], which is consistent
with prior reports that viral load “blips” may contribute to
CD4+ cell loss in HIV controllers [45]. In this population, the
etiology of CD4+ T cell decline may be multifactorial because
T-cell activation has also been found to be associated with
lower CD4+ cell counts [12]. It is interesting to note that al-
though initiation of ART in HIV controllers has resulted in di-
minished HIV reservoir size [46], lower levels of residual
viremia, and T-cell activation [38], it is only associated with a
modest or no increase in CD4+ cell counts [38, 47]. The etiology
behind this blunted CD4+ cell response to ART remains un-
clear. We did not ﬁnd signiﬁcant associations between the solu-
ble markers of inﬂammation and either levels of residual
viremia or CD4+ cell decline. The lack of an association between
certain inﬂammatory markers and HIV viral load in ECs have
been described previously [31] and suggests that persistent viral
replication may not be the primary driver behind the inﬂamma-
tion seen in ECs.
There are a few notable limitations to this study. Due to sam-
ple limitations, evaluations of low-level viral load were not per-
formed in the HIV-suppressed cohort, and the relationship
between plasma viral and the soluble markers of inﬂammation
were only evaluated in the ECs. Although we found no signiﬁ-
cant correlation between soluble markers of inﬂammation and
viral load, this was a largely cross-sectional retrospective study,
and the potential contribution of long-standing low-level repli-
cation cannot be ruled out. Larger longitudinal interventional
studies are needed in ECs, given a previous report suggesting
possible declines in soluble inﬂammatory markers after ART
initiation [38]. It is possible that ART treatment can at least par-
tially restore immune reconstitution of gut-associated lymphoid
tissue and lymphatic tissue architecture [48], leading to eventual
decreases in soluble inﬂammatory markers, especially from
monocyte/macrophage activation. Although we did not detect
signiﬁcant associations between soluble markers of inﬂamma-
tion and CD4+ T-cell slope, CD4+ cell slopes have large coefﬁ-
cients of variation [49], and a larger sample size may be needed
to fully explore these relationships.
CONCLUSIONS
Historically, HIV-1 ECs were thought to be a privileged popu-
lation at relatively little risk of HIV progression and clinical dis-
ease. However, it is now clear that ECs have higher levels of
chronic inﬂammation than non-ECs on ART and are at in-
creased risk for HIV disease progression and non-AIDS events.
Our results show that ECs had a number of elevated levels of
markers inﬂammation that were not associated with plasma
viral load. In addition, the clinical predictive value of individual
soluble markers of inﬂammation may improve with multivari-
ate biomarker proﬁle modeling. In ECs, viral load was associat-
ed with CD4+ T cell decline, but not inﬂammatory marker
levels. Thus, a multifaceted interventional approach may be
needed to optimally reduce the heightened inﬂammatory proﬁle
of these individuals. A prospective treatment study sponsored
by the AIDS Clinical Trials Group (ACTG A5308) to evaluate
the impact of ART in ECs is currently underway.
Supplementary Data
Supplementary material is available online at Open Forum Infectious Diseases
(http://OpenForumInfectiousDiseases.oxfordjournals.org/).
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